Skip to content
Peptigraph home

Semaglutide and Tirzepatide Together: What Is Known

Semaglutide and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[20]GLP-1 & metabolicGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[21]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

  • SURMOUNT-5: head-to-head randomized trial of tirzepatide versus semaglutide in adults with obesity. · PMID 40353578
  • SURPASS-2: head-to-head randomized trial of tirzepatide versus semaglutide 1 mg in type 2 diabetes. · PMID 34170647
  • Observational cohort study comparing weight loss on tirzepatide and semaglutide (not randomized). · PMID 38976257
  • Real-world observational cohort comparing semaglutide with tirzepatide for cardiovascular outcomes (not randomized). · PMID 41491349
  • Claims-data cohort study in HFpEF that includes a head-to-head tirzepatide versus semaglutide comparison (not randomized). · PMID 40886075
Drug interactions named on the FDA label:
  • Zepbound label, Indications and Usage (Limitations of Use; not Section 7): coadministration with any GLP-1 receptor agonist is not recommended. · FDA label
  • Wegovy label, Indications and Usage (Limitations of Use; not Section 7): concomitant use with any other GLP-1 receptor agonist is not recommended. · FDA label
The studies above describe research settings, not a recommendation to combine them. Ask the prescriber who manages both.
Each component

Side by side

Showing 8 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldSemaglutideTirzepatide
ClassGLP-1 agonistGLP-1 / GIP dual agonist
Also calledsema, Ozempic, Wegovy, Rybelsus, Wegovy pilltirz, tirze, Mounjaro, Zepbound
FDA statusFDA approved (Ozempic, Wegovy, Rybelsus)FDA approved (Mounjaro, Zepbound)
Half-lifeapproximately 1 weeksubcutaneous · FDA label (Ozempic)approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised23 human (19 randomized or controlled) of 27 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
US searches per month368,000 · −38% searches1,220,000 · +30% searches
Related tools

Semaglutide vs Tirzepatide

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison
ComparisonTirzepatide vs Semaglutide

What people search

  • tirzepatide and semaglutide720/mo
  • ozempic and mounjaro720/mo
  • ozempic mounjaro590/mo
  • mounjaro ozempic390/mo
  • ozempic tirzepatide320/mo
  • zepbound semaglutide260/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  7. 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  8. 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  11. 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  12. 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  13. 13PubMed search: (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
  15. 15Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA internal medicine · 2024PMID 38976257Accessed 2 Oct 2026
  16. 16Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes, obesity & metabolism · 2026PMID 41491349Accessed 2 Oct 2026
  17. 17Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA · 2025PMID 40886075Accessed 2 Oct 2026
  18. 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  19. 19WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  20. 20Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  21. 21Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026

Found an error? Report a correction.